191 related articles for article (PubMed ID: 15999217)
1. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
Hill S; Khullar V; Wyndaele JJ; Lheritier K;
Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
[TBL] [Abstract][Full Text] [Related]
2. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
Cardozo L; Dixon A
J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
[TBL] [Abstract][Full Text] [Related]
4. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Foote J; Glavind K; Kralidis G; Wyndaele JJ
Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
[TBL] [Abstract][Full Text] [Related]
5. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD
BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
[TBL] [Abstract][Full Text] [Related]
7. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
Steers W; Corcos J; Foote J; Kralidis G
BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F
Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
Zinner N; Tuttle J; Marks L
World J Urol; 2005 Sep; 23(4):248-52. PubMed ID: 16096831
[TBL] [Abstract][Full Text] [Related]
10. Darifenacin in the treatment of overactive bladder.
Haab F
Drugs Today (Barc); 2005 Jul; 41(7):441-52. PubMed ID: 16193097
[TBL] [Abstract][Full Text] [Related]
11. Darifenacin: in the treatment of overactive bladder.
Croom KF; Keating GM
Drugs Aging; 2004; 21(13):885-92; discussion 893-4. PubMed ID: 15493952
[TBL] [Abstract][Full Text] [Related]
12. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
[TBL] [Abstract][Full Text] [Related]
13. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
Hill S; Elhilali M; Millard RJ; Dwyer PL; Lheritier K; Kawakami FT; Steel M
Curr Med Res Opin; 2007 Nov; 23(11):2697-704. PubMed ID: 17892634
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
15. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder.
Chapple CR
Expert Opin Investig Drugs; 2004 Nov; 13(11):1493-500. PubMed ID: 15500396
[TBL] [Abstract][Full Text] [Related]
16. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.
Zinner N
Expert Opin Pharmacother; 2007 Mar; 8(4):511-23. PubMed ID: 17309345
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
Kay GG; Wesnes KA
BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
[TBL] [Abstract][Full Text] [Related]
18. Darifenacin in the treatment of overactive bladder.
Parsons M; Robinson D; Cardozo L
Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
20. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
